Gliomas are the most common central nervous system tumors. New technologies, including
genetic research and advanced statistical methods, revolutionize the therapeutic approach …

Circulating tumor cells (CTCs) are accessible by liquid biopsies via an easy blood draw.
They represent not only the primary tumor site, but also potential metastatic lesions, and …

Molecular similarities between embryonic and malignant cells can be exploited to target
tumors through specific signatures absent in healthy adult tissues. One such embryonic …

Histopathological examination (biopsy) is the “gold standard” for the diagnosis of colorectal
cancer (CRC). However, biopsy is an invasive method, and due to the temporal and spatial …

Circulating tumor cells (CTCs) have emerged as pivotal biomarkers with significant
predictive and prognostic implications in solid tumors. Their presence in peripheral blood …

Gliomas, particularly glioblastoma (GBM), represent the most prevalent and aggressive
tumors of the central nervous system (CNS). Despite recent treatment advancements, patient …

In recent years, liquid biopsy has emerged as an alternative method to diagnose and
monitor tumors. Compared to classical tissue biopsy procedures, liquid biopsy facilitates the …

Background Gliomas are the most common and aggressive tumors of the central nervous
system. A robust and widely used blood-based biomarker for glioma has not yet been …

Gliomas are a heterogenous group of central nervous system tumors with different outcomes
and different therapeutic needs. Glioblastoma, the most common subtype in adults, has a …

Various biomarkers targeting cell-free DNA (cfDNA) and circulating proteins have been
tested for pan-cancer detection. Oncofetal chondroitin sulfate (ofCS), which distinctively …